Dose Escalation Study of AST-OPC1 in Spinal Cord Injury
https://clinicaltrials.gov/ct2/show/NCT02302157?term=OPC1&rank=1
Categories
Category: Stem cells
Ira Pastor, ideaXme exponential health ambassador and founder of Bioquark, interviews Dr Wise Young M.D., Ph.D., the Richard H. Shindell Chair in Neuroscience, Distinguished Professor of Cell Biology & Neuroscience and the Founding Director of the W. M. Keck Center for Collaborative Neuroscience at Rutgers University.
Alliance for Regenerative Medicine (ARM) Neuralstem Presentation
April 17, 2018
Neuralstem is a clinical-stage biopharmaceutical company developing novel treatments for nervous system diseases of high unmet medical need. The company’s lead asset and stem cell therapy candidate, NSI-566, is a spinal cord-derived neural stem cell line being tested in Amyotrophic Lateral Sclerosis (ALS), chronic spinal cord injury (cSCI) and ischemic stroke. Additionally, NSI-189, is a chemical entity in development for major depressive disorder (MDD) and for Angelman syndrome, irradiation-induced cognitive impairment, neuropathy associated with Type 1 and Type 2 diabetes and stroke. These product candidates are based on the company’s proprietary neural stem cell technology. http://www.neuralstem.com